(0.09%) 5 521.75 points
(0.12%) 39 892 points
(0.20%) 19 790 points
(-0.01%) $81.62
(0.60%) $2.83
(-0.28%) $2 337.80
(0.17%) $29.58
(0.27%) $1 004.50
(0.02%) $0.932
(-0.05%) $10.53
(0.00%) $0.788
(-2.06%) $86.18
0.84% $ 63.75
@ $63.65
Wydano: 24 birž. 2024 @ 19:15
Zwrot: 0.16%
Poprzedni sygnał: birž. 21 - 22:00
Poprzedni sygnał:
Zwrot: 1.26 %
Live Chart Being Loaded With Signals
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 2.48M |
Średni wolumen | 3.34M |
Kapitalizacja rynkowa | 14.33B |
EPS | $0.760 ( Q1 | 2024-04-30 ) |
Następna data zysków | ( $1.140 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
19.32 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.310 (2.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-12 | Baker Bros. Advisors Lp | Buy | 2 830 | Common Stock |
2024-06-12 | Baker Bros. Advisors Lp | Sell | 5 283 206 | Common Stock |
2024-06-12 | Baker Bros. Advisors Lp | Buy | 2 830 | Common Stock |
2024-06-12 | Baker Bros. Advisors Lp | Sell | 175 977 | Common Stock |
2024-06-12 | Baker Bros. Advisors Lp | Buy | 12 517 | Non- Qualified Stock Options (right to buy) |
INSIDER POWER |
---|
-77.58 |
Last 98 transactions |
Buy: 962 698 | Sell: 5 597 088 |
Wolumen Korelacja
Incyte Corp Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ADPT | 0.947 |
NDLS | 0.938 |
NEOG | 0.928 |
RNW | 0.928 |
BIGC | 0.926 |
CWCO | 0.924 |
DCFC | 0.923 |
MAXN | 0.923 |
CLNE | 0.922 |
NVTS | 0.922 |
10 Najbardziej negatywne korelacje | |
---|---|
SWAV | -0.903 |
TAYD | -0.895 |
IVCB | -0.887 |
BCSA | -0.887 |
FTGC | -0.883 |
JVA | -0.882 |
KINS | -0.88 |
MTEK | -0.873 |
EML | -0.871 |
LPCN | -0.869 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Incyte Corp Korelacja - Waluta/Towar
Incyte Corp Finanse
Annual | 2023 |
Przychody: | $3.70B |
Zysk brutto: | $3.44B (93.10 %) |
EPS: | $2.67 |
FY | 2023 |
Przychody: | $3.70B |
Zysk brutto: | $3.44B (93.10 %) |
EPS: | $2.67 |
FY | 2022 |
Przychody: | $3.39B |
Zysk brutto: | $3.19B (93.90 %) |
EPS: | $1.530 |
FY | 2021 |
Przychody: | $2.99B |
Zysk brutto: | $2.84B (94.94 %) |
EPS: | $4.30 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej